<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>4-Fluoroamphetamine - Complete Profile</title>
    <link rel="stylesheet" href="/style.css">
</head>

<body>
  <body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/">Home</a>
          </li>
          <li>
            <a href="/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/about/">About</a>
          </li>
          <li>
            <a href="/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/stimulants/">Stimulants</a> ‚Üí <span>4-Fluoroamphetamine</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>‚ö° 4-Fluoroamphetamine</h1>
        <h2 class="chemical-name">4-Fluoroamphetamine</h2>
          
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="4-Fluoroamphetamine" 
                data-category="Stimulants" 
                data-chemical="4-Fluoroamphetamine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>4-FA</span> ‚Ä¢ <span>4-FMP</span> ‚Ä¢ <span>PAL-303</span> ‚Ä¢ <span>Flux</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Clean Speed</span> ‚Ä¢ <span>Empathetic Amphetamine</span> ‚Ä¢ <span>Study Molly</span>
            </div>
            <div class="name-category">
              <h4>Chemical Names</h4>
              <span>para-Fluoroamphetamine</span> ‚Ä¢ <span>4-Fluoro-Œ±-methylphenethylamine</span>
            </div>
            <div class="name-category">
              <h4>Research Designations</h4>
              <span>4-FA¬∑HCl</span> ‚Ä¢ <span>p-Fluoroamphetamine</span> ‚Ä¢ <span>4-FMA</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category stimulant-empathogen">Stimulant-Empathogen</span>
          <span class="legal-status unscheduled">Unscheduled</span>
          <span class="duration long">6-10 hours</span>
          <span class="research-chemical">Research Chemical</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/4-fluoroamphetamine.jpg" alt="4-Fluoroamphetamine white crystalline powder with molecular structure showing fluorine substitution at para position" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇâH‚ÇÅ‚ÇÇFN</p>
            <p>MW: 153.20 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure 4-FA (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine powder, sometimes small crystals</li>
            <li><strong>Odor:</strong> Virtually odorless when pure</li>
            <li><strong>Taste:</strong> Bitter, slightly numbing</li>
            <li><strong>Solubility:</strong> Highly soluble in water and alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Research Chemical Forms</h4>
          <ul>
            <li><strong>Powder:</strong> Most common form, white to slightly off-white</li>
            <li><strong>Capsules:</strong> Pre-measured doses in gelatin capsules</li>
            <li><strong>Pellets:</strong> Pressed tablets with exact dosing</li>
            <li><strong>Liquid solutions:</strong> Dissolved in ethanol or propylene glycol</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Common Issues</h4>
          <p><strong>Substitution:</strong> Often confused with 2-FA, 3-FA, or other fluoroamphetamines</p>
          <p><strong>Impurities:</strong> Synthesis byproducts, unreacted starting materials</p>
          <p><strong>Misrepresentation:</strong> Sometimes sold as "clean MDMA" or amphetamine</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">15-30mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">30-60mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">60-100mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">100-150mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">150mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Dosage Considerations</h4>
        <ul>
          <li><strong>Dual-phase effects:</strong> Lower doses more stimulating, higher doses more empathogenic</li>
          <li><strong>Long duration:</strong> 6-10 hours total, plan accordingly</li>
          <li><strong>Individual sensitivity:</strong> Start low - responses vary significantly</li>
          <li><strong>Redosing:</strong> Generally not recommended due to long duration</li>
          <li><strong>Tolerance:</strong> Develops with regular use, take breaks</li>
          <li><strong>Route differences:</strong> Insufflation more intense but shorter duration</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> 4-FA has a long duration and dose-dependent effect profile. Start with lower doses to assess individual sensitivity.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Oral)</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:30</span>
          <span class="effect">Onset - increased focus, mild euphoria</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:30-4:00</span>
          <span class="effect">Peak - stimulation dominant, empathogenic undertones</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Plateau - sustained effects, empathy more prominent</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-12:00</span>
          <span class="effect">Comedown - gradual decline, possible insomnia</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Positive Effects</h4>
          <ul>
            <li>Enhanced focus and concentration</li>
            <li>Increased energy and motivation</li>
            <li>Mild empathogenic effects</li>
            <li>Enhanced sociability</li>
            <li>Mood elevation and euphoria</li>
            <li>Increased mental clarity</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Negative Effects</h4>
          <ul>
            <li>Insomnia and sleep disruption</li>
            <li>Jaw clenching and teeth grinding</li>
            <li>Increased heart rate and blood pressure</li>
            <li>Appetite suppression</li>
            <li>Anxiety and restlessness</li>
            <li>Post-experience fatigue</li>
          </ul>
        </div>
      </div>

      <div class="dose-dependent-effects">
        <h4>üìä Dose-Dependent Effect Profile</h4>
        <div class="dose-effect-ranges">
          <div class="effect-range">
            <span class="dose-label">30-60mg</span>
            <span class="effect-description">Primarily stimulating - focus, energy, mild mood lift</span>
          </div>
          <div class="effect-range">
            <span class="dose-label">60-100mg</span>
            <span class="effect-description">Balanced - stimulation with noticeable empathogenic qualities</span>
          </div>
          <div class="effect-range">
            <span class="dose-label">100mg+</span>
            <span class="effect-description">Empathogen-dominant - strong emotional effects, sociability</span>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>4-Fluoroamphetamine is a substituted amphetamine that acts as a releasing agent and reuptake inhibitor for dopamine, norepinephrine, and serotonin. The fluorine substitution at the 4-position (para position) increases serotonergic activity compared to regular amphetamine, creating the unique stimulant-empathogen hybrid profile. It reverses the direction of monoamine transporters while blocking reuptake.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>DAT (Dopamine transporter)</strong></span>
            <span class="affinity">High affinity (IC50: ~50 nM)</span>
            <span class="function">Primary stimulant effects, focus, motivation, euphoria</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (Norepinephrine transporter)</strong></span>
            <span class="affinity">High affinity (IC50: ~30 nM)</span>
            <span class="function">Alertness, energy, cardiovascular effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (Serotonin transporter)</strong></span>
            <span class="affinity">Moderate affinity (IC50: ~200-500 nM)</span>
            <span class="function">Empathogenic effects, mood elevation, sociability</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>5-HT2A receptor</strong></span>
            <span class="affinity">Weak agonist activity</span>
            <span class="function">Mild perceptual changes, enhanced sensory perception</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Trace amine receptors</strong></span>
            <span class="affinity">Agonist activity</span>
            <span class="function">Modulation of monoamine release</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary metabolism:</strong> Hepatic deamination by MAO-A and MAO-B</p>
          <p><strong>Secondary pathways:</strong> Aromatic hydroxylation, conjugation reactions</p>
          <p><strong>Half-life:</strong> 6-8 hours (effects last longer due to active metabolites)</p>
          <p><strong>Bioavailability:</strong> ~80-90% oral administration</p>
          <p><strong>Peak plasma:</strong> 1-3 hours after oral dose</p>
          <p><strong>Fluorine effect:</strong> Slows metabolism, extends duration vs. amphetamine</p>
        </div>

        <h4>Fluorine Substitution Effects</h4>
        <div class="fluorine-effects">
          <p><strong>Increased serotonergic activity:</strong> Para-fluorine substitution enhances SERT affinity</p>
          <p><strong>Metabolic stability:</strong> Fluorine bond resistant to enzymatic breakdown</p>
          <p><strong>Duration extension:</strong> Slower metabolism results in longer-lasting effects</p>
          <p><strong>Reduced peripheral effects:</strong> Less cardiovascular stress than regular amphetamine</p>
          <p><strong>Unique profile:</strong> Creates stimulant-empathogen hybrid not seen in unsubstituted amphetamine</p>
        </div>

        <h4>Neurotoxicity Considerations</h4>
        <div class="neurotoxicity-info">
          <p><strong>Serotonergic concerns:</strong> Chronic use may affect serotonin terminals similar to MDMA</p>
          <p><strong>Dopaminergic effects:</strong> Potential for dopamine terminal damage with heavy use</p>
          <p><strong>Hyperthermia risk:</strong> Less than MDMA but still present at high doses</p>
          <p><strong>Limited research:</strong> Long-term effects not well studied in humans</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Dual-phase profile:</strong> Dose-dependent shift from stimulant to empathogen</li>
          <li><strong>Extended duration:</strong> Longer lasting than most stimulants or empathogens</li>
          <li><strong>Balanced monoamine release:</strong> More balanced DA/NE/5-HT activity than amphetamine</li>
          <li><strong>Smooth comedown:</strong> Generally less harsh than regular amphetamine</li>
          <li><strong>Functional stimulation:</strong> Maintains cognitive enhancement with emotional warmth</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Cardiovascular stress:</strong> Increased heart rate and blood pressure</li>
            <li><strong>Hyperthermia risk:</strong> Potential overheating, especially with physical activity</li>
            <li><strong>Long duration:</strong> 8-12 hours total, plan accordingly</li>
            <li><strong>Sleep disruption:</strong> Can cause severe insomnia</li>
            <li><strong>Unknown long-term effects:</strong> Limited human safety data</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Precautions</h4>
          <ul>
            <li>Start with low doses to assess individual sensitivity</li>
            <li>Stay hydrated but avoid excessive water intake</li>
            <li>Monitor body temperature, stay cool</li>
            <li>Avoid strenuous physical activity</li>
            <li>Plan for extended duration and potential insomnia</li>
            <li>Don't use if you have cardiovascular issues</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Heart conditions, high blood pressure, hyperthyroidism, glaucoma, psychiatric disorders, or are taking MAOIs, antidepressants, or other stimulants.</p>
      </div>

      <div class="harm-reduction-specific">
        <h4>4-FA Specific Harm Reduction</h4>
        <ul>
          <li><strong>Duration planning:</strong> Don't dose late in day due to 10+ hour duration</li>
          <li><strong>Redose avoidance:</strong> Long duration makes redosing unnecessary and risky</li>
          <li><strong>Tolerance breaks:</strong> Take regular breaks to prevent rapid tolerance buildup</li>
          <li><strong>Supplement wisely:</strong> Magnesium for jaw clenching, melatonin for sleep recovery</li>
          <li><strong>Social setting:</strong> Higher doses best used in social rather than work settings</li>
        </ul>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Extremely Dangerous</h4>
          <ul>
            <li><strong>MAOIs:</strong> Risk of hypertensive crisis and serotonin syndrome</li>
            <li><strong>Other stimulants:</strong> Excessive cardiovascular strain, hyperthermia</li>
            <li><strong>Tramadol:</strong> Increased seizure risk, serotonin syndrome</li>
            <li><strong>SSRIs/SNRIs:</strong> Serotonin syndrome, reduced effects</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Alcohol:</strong> Masks intoxication, dehydration, liver stress</li>
            <li><strong>DXM:</strong> Serotonin syndrome risk</li>
            <li><strong>MDMA:</strong> Dangerous serotonin overload</li>
            <li><strong>Cannabis:</strong> May increase anxiety or paranoia</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>Caffeine:</strong> Increased anxiety and cardiovascular effects</li>
            <li><strong>Psychedelics:</strong> May intensify or prolong experience</li>
            <li><strong>Depressants:</strong> Masking of effects, dangerous combinations</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Unscheduled federally</strong> - However, may be prosecuted under Federal Analogue Act as an amphetamine analogue. Some states have specific bans.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class B</strong> - Illegal under generic amphetamine legislation. Up to 5 years for possession, 14 for supply.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá≥üá± Netherlands</h4>
            <p><strong>List I</strong> - Scheduled as controlled substance. Illegal to manufacture, distribute, or possess.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá™üá∫ European Union</h4>
            <p><strong>Varies by country</strong> - Many EU countries have banned fluoroamphetamines under generic scheduling.</p>
          </div>
        </div>
        
        <div class="legal-trends">
          <h4>‚öñÔ∏è Legal Evolution</h4>
          <p>4-FA is increasingly being banned worldwide as authorities expand amphetamine scheduling to include fluorinated analogues. Legal status is rapidly changing in many jurisdictions.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1960s</span>
          <p>First synthesized as part of systematic amphetamine analogue research</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Pharmacological characterization in academic research</p>
        </div>
        <div class="history-event">
          <span class="year">2007</span>
          <p>Emerges on research chemical market in Netherlands</p>
        </div>
        <div class="history-event">
          <span class="year">2010-2015</span>
          <p>Peak popularity as "clean" amphetamine alternative</p>
        </div>
        <div class="history-event">
          <span class="year">2017</span>
          <p>Netherlands bans 4-FA, reducing global availability</p>
        </div>
        <div class="history-event">
          <span class="year">2020s</span>
          <p>Increasing international scheduling and restrictions</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Research Chemical Culture</h4>
        <p>4-FA gained popularity as the "perfect stimulant" - combining the productivity benefits of amphetamine with the social warmth of MDMA. It became especially popular among students and professionals seeking functional enhancement without the harsh side effects of traditional stimulants.</p>
        
        <h4>Functional Enhancement Movement</h4>
        <p>4-FA represents the research chemical community's attempt to engineer better stimulants - substances that enhance performance while maintaining emotional warmth and social connection.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Pharmacological Profiling</h4>
          <p>Limited academic research into receptor binding profiles and comparing activity to other fluoroamphetamines and parent compounds.</p>
        </div>
        
        <div class="research-item">
          <h4>Neurotoxicity Studies</h4>
          <p>Preliminary animal studies examining potential for serotonergic neurotoxicity similar to MDMA, with mixed results.</p>
        </div>
        
        <div class="research-item">
          <h4>Metabolism Research</h4>
          <p>Studies identifying metabolic pathways and comparing clearance rates to other amphetamines to understand duration differences.</p>
        </div>
        
        <div class="research-item">
          <h4>Forensic Detection</h4>
          <p>Development of analytical methods for detecting 4-FA and its metabolites in biological samples for legal and medical purposes.</p>
        </div>
      </div>

      <div class="research-limitations">
        <h4>üö´ Research Limitations</h4>
        <p>Human research is extremely limited due to legal restrictions and lack of therapeutic potential. Most safety data comes from user reports and limited animal studies.</p>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Safety & Information Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Harm Reduction</h4>
        <ul>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - Comprehensive information</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - Community discussion and safety</li>
          <li><a href="https://erowid.org/">Erowid</a> - Experience reports and information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Testing & Analysis</h4>
        <ul>
          <li><a href="https://drugsdata.org/">DrugsData.org</a> - Lab testing service</li>
          <li><strong>Reagent testing:</strong> Marquis, Liebermann, Simon's A&B</li>
          <li><strong>Warning:</strong> Many substances sold as 4-FA are substitutes</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Academic Resources</h4>
        <ul>
          <li><a href="https://pubmed.ncbi.nlm.nih.gov/">PubMed</a> - Scientific literature</li>
          <li><strong>Pharmacology papers:</strong> Limited but available for mechanism studies</li>
          <li><strong>Case reports:</strong> Medical literature on adverse effects</li>
        </ul>
      </div>
    </div>
    
    <div class="research-chemical-warning">
      <h4>‚ö†Ô∏è Research Chemical Disclaimer</h4>
      <p><strong>4-Fluoroamphetamine is a research chemical with limited human safety data. Long-term effects are unknown, and quality control varies significantly between sources. This substance exists in a legal gray area and carries inherent risks due to lack of regulation and clinical research.</strong></p>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/js/lunr.min.js"></script>
    <script src="/assets/js/search.js"></script>
    <script src="/assets/js/substance-integration.js"></script>
</body>
</html>